EUVIMEDEUVIMED entdecken
Crossref

Risk Factors Associated With Incident Opioid Prescription Among Attention-Deficit/Hyperactivity Disorder Patients Prescribed Stimulants

Mina Shrestha, Chijioke M Okeke iD, Chan Shen, Dong-Won Kang, Douglas Leslie, Tyler Varisco, Olajumoke Olateju, Matthew Wanat, J Douglas Thornton

Annals of Pharmacotherapy · 2026

DOI: 10.1177/10600280251413628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2026. Verfasst von Mina Shrestha und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Prescription Drug Misuse Education and Research (PREMIER) Center, College of Pharmacy, University of Houston, Houston, TX, USA. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Analgesics, Opioid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Substance Abuse and Mental Health Services Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pharmacotherapy with stimulant or nonstimulant medications is recommended as first-line treatment for attention-deficit/hyperactivity disorder (ADHD). Among patients prescribed stimulants, concomitant opioid use may increase the risk of drug dependence, exacerbate comorbid conditions, and compromise treatment adherence. However, limited evidence exists on the risk factors for initial opioid prescription in this population.

Objective

To identify factors associated with incident opioid prescriptions among patients with ADHD prescribed stimulant therapy.

Methods

We conducted a retrospective cohort study using the Merative® MarketScan® Commercial Claims and Encounters Database (2010-2020). We identified patients with ADHD who initiated stimulant therapy and followed them for 1 year to assess incident opioid prescription. Cox proportional hazards models were used to evaluate factors associated with opioid initiation.

Results

Among 380 494 patients with ADHD initiating stimulants (mean age: 21.2 years; 56.5% male), 14.2% received an opioid prescription within 1 year. Factors significantly associated with incident opioid prescription included age ≥35 years (adjusted hazard ratio [aHR]: 10.84; 95% CI: 10.43-11.26), gender(aHR [female]:1.29; 95% CI: 1.27-1.31), geographic region (aHR [West]: 1.58; 95% CI: 1.52-1.64), multiple chronic conditions (aHR: 1.61; 95% CI: 1.54-1.67), anxiety (aHR: 1.19; 95% CI: 1.17-1.22), depression (aHR: 1.16; 95% CI: 1.14-1.19), severe mental illnesses (aHR: 1.18; 95% CI: 1.13-1.23), substance use disorders (SUDs) (aHR: 1.69; 95% CI: 1.63-1.75). Receipt of behavioral therapy before ADHD pharmacotherapy (aHR: 0.89; 95% CI: 0.87-0.92) was associated with a lower risk of receiving incident opioid prescriptions. Conclusions and relevance: Several demographic factors (e.g., age, gender, geographic region) and clinical factors (e.g., history of mental health conditions and SUDs) are associated with opioid initiation among stimulant-treated patients with ADHD. These findings may inform clinical strategies to mitigate unnecessary opioid exposure and associated harms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsAnalgesics, OpioidHumansFemaleRisk FactorsRetrospective StudiesMaleAdolescentYoung AdultAdultChildDrug Prescriptions

Stichwörter der Autor:innen

attention-deficit/hyperactivity disorderconcomitantopioidspharmacotherapystimulants

Substanzen

Central Nervous System StimulantsAnalgesics, Opioid

Autor:innen und Institutionen

  • The Prescription Drug Misuse Education and Research (PREMIER) Center, College of Pharmacy, University of Houston, Houston, TX, USA.
  • Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA.
  • Division of Outcomes Research and Quality, Department of Surgery, College of Medicine, Pennsylvania State University, Hershey, PA, USA.
  • Division of Health Services and Behavioral Research, Department of Public Health Sciences, College of Medicine, Pennsylvania State University, Hershey, PA, USA.
  • Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, TX, USA.

ORCID-Profile: Chijioke M Okeke

Förderung

  • Substance Abuse and Mental Health Services Administration

Zitieren

APA

Shrestha, M., Okeke, C. M., Shen, C., Kang, D. W., Leslie, D., Varisco, T., Olateju, O., Wanat, M., & Thornton, J. D. (2026). Risk Factors Associated With Incident Opioid Prescription Among Attention-Deficit/Hyperactivity Disorder Patients Prescribed Stimulants. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251413628

Vancouver

Shrestha M, Okeke CM, Shen C, Kang DW, Leslie D, Varisco T, et al. Risk Factors Associated With Incident Opioid Prescription Among Attention-Deficit/Hyperactivity Disorder Patients Prescribed Stimulants. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280251413628

BibTeX
@article{Shrestha2026,
  author = {Shrestha, Mina and Okeke, Chijioke M and Shen, Chan and Kang, Dong-Won and Leslie, Douglas and Varisco, Tyler and Olateju, Olajumoke and Wanat, Matthew and Thornton, J Douglas},
  title = {Risk Factors Associated With Incident Opioid Prescription Among Attention-Deficit/Hyperactivity Disorder Patients Prescribed Stimulants},
  journal = {Annals of Pharmacotherapy},
  year = {2026},
  doi = {10.1177/10600280251413628}
}
Kostenlos starten →